anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
PROBLEM TO BE SOLVED: To obtain the subject agent having an elastase inhibiting activity, keeping the skin taut and elasticity of, holding a state of a young skin and useful for e.g. foundation cosmetics, makeup cosmetics, hair cosmetics or bath liquids, by including a solvent extract of the plant belonging to the genus Humulus as an active agent. SOLUTION: This antiaging agent comprising a solvent extract of the plant (pref. Humus lupulus L.) belonging to the genus Humulus is obtained by subjecting an extract from the female catkin of the above plant to soaking or heat reflux process together with the extract solvent (e.g. methoanol, ethanol or 1,3-buthylene glycol), and subjecting it to filtration and concentration. The blending ratio of the extract to the whole agent for external use is 0.0001 to 10.0 wt.% based on the dried extract. The antiaging agent may be blended with e.g. a beautifully whitening agent, moisture-retaining agent, antioxidant or oil component. There may be blended e.g. disodium edetate or sodium citrate. The antiaging agent is pref. applied to cosmetics.
Disclosed are a pest control agent, a method for preparing a pest control agent, and a method for controlling a pest. Generally, the pest control agent is formed by providing a porous starch and an active control agent absorbed within the porous starch, and compressing the porous starch in the presence of heat to form discrete plural particles. Preferably, one or more binders are employed, as are one or more secondary absorbents/fillers. In highly preferred embodiments of the invention, the pest control agent is prepared via pelletizing in a commercial pellet mill. The particles so prepared should be sufficiently durable to withstand bulk transport, such as by rail car or bag shipment. The particles should, however, release the control agent quickly upon contact with water, such that, for instance, the control agent may be released when the pest control agent is introduced to standing water. It is contemplated that the control agent is preferably a mosquito control agent.
Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A\*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Methionine aminopeptidases catalyse the co-translational removal of amino terminal methionine residues from nascent polypeptide chains. A newly-discovered enzyme, designated methionine aminopeptidase type-3 (MetAP-3), has a substrate specificity which is similar to MetAP-1 and MetAP-2, although it is not inhibited by fumagillin, an irreversible inhibitor of MetAP-2. MetAP-3 also preferentially localizes to mitochondria, unlike MetAP-1 and MetAP-2, which accumulate in the cytoplasm. One embodiment of the present invention relates to human cDNAs encoding polypeptides comprising MetAP-3. Other embodiments of the invention relate to nucleic acid molecules derived from these cDNAs, including complements, homologues, and fragments thereof, and methods of using these nucleic acid molecules, to generate polypeptides and fragments thereof. Other embodiments of the invention relate to antibodies directed against polypeptides comprising MetAP-3, and methods to screen for compounds or compositions that preferentially or specifically effect the activity of polypeptides comprising MetAP-3.
Laminins are essential components of the basement membranes, expressed in a tissue- and cell-specific manner under physiological conditions. During inflammatory circumstances, such as atherosclerosis, alterations in laminin composition within vessels have been observed. Our study aimed to assess the influence of tumor necrosis factor-alpha (TNF), a proinflammatory cytokine abundantly found in atherosclerotic lesions, on endothelial laminin gene expression and the effects of laminin-332 (LN332) on endothelial cells' behavior. We also evaluated the expression of LN332-encoding genes in human carotid atherosclerotic plaques. Our findings demonstrate that TNF induces upregulation of LAMB3 and LAMC2, which, along with LAMA3, encode the LN332 isoform. Endothelial cells cultured on recombinant LN332 exhibit decreased claudin-5 expression and display a loosely connected phenotype, with an elevated expression of chemokines and leukocyte adhesion molecules, enhancing their attractiveness and adhesion to leukocytes in vitro. Furthermore, LAMB3 and LAMC2 are upregulated in human carotid plaques and show a positive correlation with TNF expression. In summary, TNF stimulates the expression of LN332-encoding genes in human endothelial cells and LN332 promotes an endothelial phenotype characterized by compromised junctional integrity and increased leukocyte interaction. These findings highlight the importance of basement membrane proteins for endothelial integrity and the potential role of LN332 in atherosclerosis.
Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
The following research project can contribute to the investigators' understanding of how/how well self-guided resources can increase participant outcomes of self-criticism, self-esteem, automatic negative self-statements, and mental health. Self-guided resources such as a self-talk journal provide can provide an easily accessible avenue for improving individual mental health. There has been a recent surge in the popularity of health-promotive self-care products, or products aimed at providing individuals with "the knowledge, skills, and attitudes required to achieve and maintain good health". These products (often in the form of journals) are similar to "self-help books"; however, a key difference is that self-care products prompt and provide space for the reader to actively engage in activities and psychological techniques, unlike the passive nature of traditional self-help books. These products typically address mental health concerns (i.e., mental health self-care) and are advertised to provide an effective means for individuals to reduce stress, improve self-compassion, and boost wellbeing. What's more, the generally positive reviews these products garner provides the perception that these products are well-received and effective in eliciting these outcomes. However, the scientific foundation for the majority of these journals is unknown. Furthermore, the efficacy of these products for improving or promoting their intended outcome(s) is often not addressed outside of these, often positive, reviews.
Protein-containing beverages are described. The beverages may include water and 2 wt. % to 8 wt. % protein (based on the total weight of the beverage). The protein in the beverage may include whey protein. The whey protein has at least 12 wt. % of the branched-chain amino acid leucine (based on the total weight of the whey protein). The beverage may also include casein protein. Methods of making protein-containing beverage products are also described. The methods may include providing a protein-containing aqueous mixture, homogenizing and pasteurizing the protein-containing aqueous mixture, and bottling the homogenized and pasteurized protein-containing aqueous mixture to form the protein-containing beverage product. The protein-containing aqueous mixture may include casein protein, and whey protein having at least 12 wt. % leucine (based on the total weight of the whey protein).
PROBLEM TO BE SOLVED: To speedily distribute and supply stored druggery by mediating between a supply side (storage side) for druggery and its consumer side (side which wishes to obtain) through a homepage by using a communication network such as the Internet and accelerating the efficient mutual accommodation of the druggery. SOLUTION: The supply side for druggery, etc., publishes information on druggery (medicine name, stock quantity, etc.), in stock, business hours, etc., in a homepage at a stored druggery information retrieval support site of a medical information service system site 5 by its terminal (one of 1a to 1k) through the Internet 2. An area is set with a zip code. As one area, a chain store such as a pharmacy is set. A consumer side (one of 1a to 1k) for druggery after confirming various information on druggery on the homepage at the site sends a written purchase request. A specific paying method, a purchase request for druggery reception conditions, etc., are sent through a mail/FAX server, etc., at the site by being written to a FAX request form on the homepage.  The operator of the stored druggery information retrieval support site only provides a place where information on stored druggery is exchanged and does not participate in the mentioned transaction at all.
Fifty patients with soft tissue ridge contour defects in the maxillary premolar region and recommended for rehabilitation by an implant or a fixed restoration will be enrolled. Patients will be allocated randomly into two groups; group 1 (test group) will have augmentation for their soft tissue by a novel Denuded interpositional pedicled rolled flap technique (DIPRF); group 2 (control group) will be augmented by the conventional subepithelial connective tissue graft technique. Clinical volumetric change evaluation and ridge thickness analysis using digitally calibrated casts and CBCT analysis with a fusion software will be performed for every site as well as periodontal evaluation and patient centered outcomes, including pain and satisfaction after the procedure will be recorded for both techniques. For each site, an impression will be used to pour a cast that will be digitally scanned and vertical and horizontal ridge contours dimensions(tissue volumetric changes) will be recorded. These measurements will be obtained before the surgical procedure, 2 weeks, and 3 and 6 months post-surgical. CBCT analysis will be performed pre-operatively to confirm the diagnosis and eligibility of the case as having only soft tissue defect without bone defects, and 6 months postoperatively to analyze the amount of soft tissue gain in the two groups.
PROBLEM TO BE SOLVED: To obtain a rouge composition which protects lips from ultraviolet rays and has excellent usability by formulating a specific compound dissolving in silicone oil, excellent in resistance to water and oil and absorbing ultraviolet rays of the wavelength in the UV-AB zone. SOLUTION: This rouge composition contains a silicone benzophenone derivative as an active ingredient. The compound of the formula shows high compatibility to a silicone base agent. The amount of the compound of the formula is 0.1-20wt.%, preferably 2.0-10wt.% in this composition. As a base agent for the rouge composition, is preferably cited a silicone base material, for example, dimethylpolysiloxane, decamehtylpolysiloxane, amino-modified polysiloxane or the like. The objective rouge composition shows good adhesion to lips, can be readily applied and resists being rubbed off with a physical force.
the following acute, randomized crossover study will be completed in 12 healthy adults (age 18-35y; BMI: 18-29.9 kg/m2) to compare 135 kcal protein beverages consumed at breakfast containing 30 g of protein from whey isolate (WY), casein (CS), egg white isolate (EWI), egg white protein concentrate (EWP), or a 0 kcal water beverage - which serves as the control (CON). Note: the W beverage will be consumed on 2 different days; these days only differ by the postprandial outcomes completed (see below).

The participants will report to the research facility between 7 - 9 am to complete each 4-h testing day. Prior to testing, the participants will be provided with a standardized dinner to consume, at home, between 5-7 pm the night before each testing day. Upon arrival to the facility, each participant will become familiarized with the testing day procedures. At time -15 min, a baseline set of computerized questionnaires will be completed. At time 0 min, one of the breakfast beverages will be provided. Immediately following the first swallow of the breakfast shakes, the participants will be given a questionnaire assessing the palatability of each shake. The participants will consume the beverage within 20 min. For 5 of the 6 days, a set of questionnaires will be completed every 30 min throughout the 4-h postprandial period. For one of the W days, no questionnaires will be completed. After the 4-h, the participants will be given an ad libitum pasta meal to assess energy intake. For the lunch meal, the participants will be given 30 min to "consume as much or as little as possible until comfortably full." Following these procedures, the participants will be allowed to leave the facility. The next day, a dietary recall will be performed to assess daily energy intake following the consumption of the previous day's breakfast beverage.
At present, it appears that the prognosis for subarachnoid haemorrhage (SAH), which has a high death and disability rate, cannot be greatly improved by medication or other treatment. Recent research suggests that different types of cell death are implicated in early brain injury (EBI) after SAH, and this has been recognised as a major factor impacting the prognosis of SAH. Ferroptosis, which is a recently identified imbalance of iron metabolism and programmed cell death triggered by phospholipid peroxidation, has been shown to be involved in EBI after SAH and is thought to have a significant impact on EBI. The decomposition of cleaved haemoglobin during SAH involves the release of enormous amounts of free iron, resulting in iron metabolism disorders. Potential therapeutic targets for the signalling pathways of iron metabolism disorders and ferroptosis after SAH are constantly being discovered. To serve as a guide for research into other possible therapeutic targets, this paper will briefly describe the mechanisms of dysregulated iron metabolism and ferroptosis in the pathogenesis of SAH and highlight how they are involved in the development and promotion of EBI in SAH.
The method for treating the chronic obstructive pulmonary disease includes the use nebulizer therapy with broncholytics. Beforehand, the spirography is provided. When the forced expiratory volume in the first second (12 %, Nebutamol in the volume of 1 mL is prescribed in combination with Nebufluozon in the volume of 1 mL with 0.9 % physiologic saline for 7-10 days. When the forced expiratory volume in the first second < 12 %, Berodual (10-15 drops) is used instead of Nebutamol. The compression nebulizer with pre-selected programming of inhalation and exhalation mode is used (in emphysematous type of bronchial obstruction, expiration time is increased 1.5-fold as compared with bronchitic type of bronchial obstruction). The aerosol is released only during inspiration of the patient.
Proteinaceous hormones of animal origin are activated for administration to humans by treatment with proteolytic enzymes to a desired degree of hydrolysis, followed by inactivation of the enzyme by means of a non-toxic inhibiting substance specific to the enzyme used.  The animal hormone may be pituitary gland hormones, especially the somatotropic hormone.  The inhibitors may be (a) vegetable e.g. lima bean or soy bean inhibitor; (b) animal e.g. ovomucoids, peptidase inhibitors extracted from pancreas porotids or ascaris; or (c) chemical e.g. diisofluorophosphates.  The required degree of hydrolysis is 25 to 35% of the total hydrolysis.  The inhibitor terminates the hydrolysis and inhibits further enzyme activity of the hormone, even when the product is administered with separation of the inhibitor/enzyme complex.  The complex may be removed by dialysis at pH 6-8 and removal of the precipitated active components.
Membrane-active antimicrobial materials are promising substances to fight antimicrobial resistance. Herein, crystallization-driven self-assembly (CDSA) is employed for the preparation of nanoparticles with different morphologies, and their bioactivity is explored. Block copolymers (BCPs) featuring a crystallizable and antimicrobial block were synthesized using a combination of ring-opening and photoiniferter RAFT polymerizations. Subsequently formed nanostructures formed by CDSA could not be deprotected without degradation of the structures. CDSA of deprotected BCPs yielded 2D diamond-shaped nanoplatelets in MeOH, while spherical nanostructures were observed for assembly in water. Platelets exhibited improved antibacterial capabilities against two Gram-negative bacteria (Escherichia coli and Pseudomonas aeruginosa) compared to their spherical counterparts. The absence of hemolytic activity leads to the excellent selectivity of platelets. A mechanism based on membrane permeabilization was confirmed via dye-leakage assays. This study emphasized the impact of the shape of nanostructures on their interaction with bacterial cells and how a controlled assembly can improve bioactivity.
BACKGROUND: Chemical modifications on RNA profoundly affect RNA function and regulation. m6A, the most abundant RNA modification in eukaryotes, plays a pivotal role in diverse cellular processes and disease mechanisms. However, its importance is understudied in human CKD samples regarding its influence on pathological mechanisms.
METHODS: Liquid chromatography–tandem mass spectrometry and methylated RNA immunoprecipitation sequencing were used to examine alterations in m6A levels and patterns in CKD samples. Overexpression of the m6A writer METTL3 in cultured kidney tubular cells was performed to confirm the effect of m6A in tubular cells and explore the biological functions of m6A modification on target genes. In addition, tubule-specific deletion of Mettl3 (Ksp-Cre Mettl3f/f) mice and antisense oligonucleotides inhibiting Mettl3 expression were used to reduce m6A modification in an animal kidney disease model.
RESULTS: By examining 127 human CKD samples, we observed a significant increase in m6A modification and METTL3 expression in diseased kidneys. Epitranscriptomic analysis unveiled an enrichment of m6A modifications in transcripts associated with the activation of inflammatory signaling pathways, particularly the cyclic guanosine monophosphate–AMP synthase (cGAS)-stimulator of IFN genes (STING) pathway. m6A hypermethylation increased mRNA stability in cGAS and STING1 as well as elevated the expression of key proteins within the cGAS-STING pathway. Both the tubule-specific deletion of Mettl3 and the use of antisense oligonucleotides to inhibit Mettl3 expression protected mice from inflammation, reduced cytokine expression, decreased immune cell recruitment, and attenuated kidney fibrosis.
CONCLUSIONS: Our research revealed heightened METTL3-mediated m6A modification in fibrotic kidneys, particularly enriching the cGAS-STING pathway. This hypermethylation increased mRNA stability for cGAS and STING1, leading to sterile inflammation and fibrosis.
OBJECTIVE: This investigation aims to evaluate the effectiveness of the paravertebral injection of recombinant human interferon-α2b in conjunction with high-voltage, long-term, pulsed radiofrequency (PRF) in the dorsal root ganglion for the mitigation of postherpetic neuralgia (PHN).
METHODS: This retrospective study included 84 individuals with acute PHN. The participants were divided into 3 groups. Group H was treated with interferon-α2b combined with high-voltage long-term PRF. Group C was treated with a combination of high-voltage, long-term PRF and a paravertebral injection (without recombinant human interferon-α2b), and group I was treated with interferon-α2b only. All the patients in the 3 groups were orally administered a 5-mg morphine hydrochloride quick-release tablet when a burst of pain occurred during treatment. The numerical rating scale for pain score, the interleukin-6 and galectin-3 levels, and the incidence of PHN were documented before and after therapy.
RESULTS: The pain intensity of all individuals decreased after therapy. Compared with group C, the numerical rating scale scores for group H were significantly reduced at 4, 8, and 12 weeks following therapy, and the PHN incidence was significantly lower. Compared with prior treatment, the recommended dosage of gabapentin capsules and immediate-release morphine hydrochloride tablets was reduced for group H. Compared with group C, the requirement for orally administrated gabapentin capsules and morphine hydrochloride tablets in group H was reduced significantly after treatment. No serious adverse reactions occurred in any of the 3 groups.
CONCLUSIONS: Within the context of treatment of acute PHN, the injection of interferon-α2b in conjunction with high-voltage, long-term application of PRF is more effective than PRF or the injection of interferon-α2b alone.
A cross-sectional study was conducted on 147 stroke patients at the Physiotherapy Department of the University of Lahore Teaching Hospital, located on Defense Road, Lahore. The study was completed within a span of 9 months following the approval of the research synopsis. A non-probability convenient sampling technique was employed for participant selection. The inclusion criteria encompassed patients who had been diagnosed with stroke, were aged between 35 to 65 years, and possessed the ability to comprehend and communicate verbally in the Urdu language. Conversely, patients with other neurological conditions such as Parkinson's disease, Alzheimer's disease, or dementia, as well as unconscious individuals, were excluded from the study. Additionally, patients with musculoskeletal and orthopedic conditions that could potentially impact the functioning of their upper and lower extremities were also excluded.

All patients provided written informed consent, and approval was obtained from the Ethics Committee of the University of Lahore. The translated Urdu version of the SS-QOL questionnaire was utilized for data collection, following a four-step procedure. Initially, two native Urdu speakers independently translated the SS-QOL into Urdu. One translator had medical expertise, while the other came from a non-medical background (T1, T2). Their translations were merged into a single version. Subsequently, this combined version was translated back into English by two professional translators (BT1, BT2) who were unfamiliar with the questionnaire and medical terminology, ensuring consistent English translation. A research committee comprising physiotherapists, an orthopedic surgeon, translators, a language expert, and authors held a meeting. This committee assessed all versions of the SS-QOL (T1, T2, T-12, BT1, BT2, B-12) for alignment with Urdu cultural nuances and methodological accuracy. They approved a pre-final SS-QOL version after methodological and grammatical analysis. Seventy patients confirmed their comprehension of the questions (pilot testing), and their feedback was deliberated upon by the authors. A final Urdu version of the SS-QOL was then established.